Pharmacokinetic Profile and Dermatomal Coverage of the Erector Spinae Plane Block

Summary

The goals of this study are as follows: 1. to confirm the safe dosing of ropivacaine for the erector spinae plane block 2. develop a pharmacokinetic profile of the erector spinae plane block, which will help demonstrate how quickly and how closely toxic levels are reached when a routine dose of ropivacaine is given for this nerve block 3. assess numbness created by the erector spinae block when routine doses are administered

Timeline

Start

2019-07-01

Primary completion

2020-07-01

Completion

2020-12-31

Outcome

Outcome not reported

Stopped (Business): “Did not receive funding”

Drugs

Indications